This inventor holds 6 USPTO granted patents and 8 published patent applications. Top assignees: Amgen Inc., Daiichi Sankyo Company, Limited, Daiichi Sankyo Europe Gmbh. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 2,074 
3 out of 463 
3 out of 16 
Years Active: 2023-2026
Title: Matthias Schneider: Innovator in Humanized Antibodies
Introduction
Matthias Schneider is a notable inventor based in Neufarn, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of three patents to his name, Schneider's work has the potential to impact cancer treatment and diagnostics.
Latest Patents
Schneider's latest patents include innovative approaches to humanized antibodies against iRHOM2. This invention relates to humanized antibodies or target-binding fragments that retain target binding capacities, specifically binding to human iRhom2. Another significant patent focuses on a protein biomarker and its uses. This invention outlines methods for identifying and treating human subjects with tumors or other diseases by assessing HRG gene expression at a protein level. It also details the administration of anti-HER3 antibodies based on the HRG gene expression levels. Additionally, Schneider's patent includes methods for performing an ELISA, which involves sequential steps of contacting a solid surface with various solutions, each containing specific components necessary for the assay.
Career Highlights
Throughout his career, Matthias Schneider has worked with prominent companies in the biotechnology sector. He has been associated with Daiichi Sankyo Company, Limited and Amgen Inc., where he has contributed to various research and development projects. His expertise in antibody development has positioned him as a valuable asset in the industry.
Collaborations
Schneider has collaborated with notable colleagues, including Sabine Blum and Renee Jeanne Mendell-Harary. These collaborations have further enhanced his research and innovation in the field of biotechnology.
Conclusion
Matthias Schneider's contributions to the development of humanized antibodies and his innovative patents reflect his dedication to advancing medical science. His work has the potential to improve treatment options for patients with tumors and other diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile